Results 131 to 140 of about 3,285,062 (216)

Pruritus Is Frequent and Persistent and Impacts Quality of Life Among Patients With Primary Sclerosing Cholangitis

open access: yesAlimentary Pharmacology &Therapeutics, Volume 64, Issue 9, Page 1288-1297, November 2026.
Among 200 patients with primary sclerosing cholangitis, 38% reported moderate to severe pruritus in the past 6 months. During 6 months of follow up, pruritus severity fluctuated significantly. Pruritus severity was linked to worse colitis activity and lower quality of life.
Richard Dean   +16 more
wiley   +1 more source

Segment‐Specific Occlusion of Retrieved Plastic Biliary Stents: Direct Quantification and Microbial and Material Determinants

open access: yesDigestive Endoscopy, Volume 38, Issue 11, November 2026.
Direct assessment of 196 plastic biliary stents from 64 patients revealed greater luminal occlusion in the proximal segment. Age ≥ 65 years, Enterococcus‐positive bile cultures, and probiotic use were associated with increased occlusion, whereas polytetrafluoroethylene‐lined stents showed less occlusion.
Akihiro Matsumi   +13 more
wiley   +1 more source

Combination therapy of ursodeoxycholic acid and budesonide for PBC–AIH overlap syndrome: a meta-analysis

open access: yes, 2015
Huawei Zhang,1,2,* Jing Yang,1,* Rong Zhu,1,3 Yuanyuan Zheng,1 Yuqing Zhou,1,2 Weiqi Dai,1 Fan Wang,1 Kan Chen,1 Jingjing Li,1 Chengfen Wang,1 Sainan Li,1 Tong Liu,1 Huerxidan Abudumijiti,1 Zheng Zhou,1,3 Jianrong Wang,1,3 Wenxia Lu,1,3 Junshan Wang,1 ...
Xia Y   +18 more
core  

Pemafibrate Improves Cholestatic Markers Regardless of the Presence of Primary Biliary Cholangitis

open access: yesHepatology Research, Volume 56, Issue 11, Page 1685-1695, November 2026.
Pemafibrate improves liver function markers related to bile flow in primary biliary cholangitis (PBC), but whether this effect is disease‐specific remains unclear. In this study, pemafibrate reduced these markers in patients with and without PBC, suggesting broader effects on bile flow beyond PBC.
Ryohei Tanigawa   +5 more
wiley   +1 more source

2-HYDROXYPROPYL-BETA-CYCLODEXTRIN COMPLEXATION WITH URSODEOXYCHOLIC ACID

open access: yes, 1995
The complexation in aqueous medium and in the solid phase of ursodeoxycholic acid (UDCA) with a highly soluble cyclodextrin, 2-hydroxypropyl-beta-cyclodextrin, was studied by means of solubility methods, IR and C-13-NMR spectroscopy, X-ray diffractometry
FORNI, Flavio   +11 more
core   +1 more source

Stability and Variability of Symptom Burden in Primary Biliary Cholangitis: Insights From a Decade of Follow‐Up

open access: yesHepatology Research, Volume 56, Issue 11, Page 1703-1712, November 2026.
Impairment of health‐related quality of life in patients with PBC, in particular observed in younger female, represents distinct dimensions of disease impact, independently of long‐term outcomes. Overall and interindividual changes in PBC‐40 scores greatly varied over 10 years, suggesting that symptom burdens are driven by heterogeneous underlying ...
Akihito Takeuchi   +22 more
wiley   +1 more source

Analyzing the Possible Hepatic Protection of Ursodeoxycholic Acid in Rat Models of Carbon Tetrachloride-Induced Hepatotoxicity

open access: yes
Background: The liver is essential for the detoxification of toxic substances as well as for metabolism, storage, and secretion. The liver is the primary organ for the metabolism of proteins, lipids, and carbohydrates. Exposure to certain xenobiotics can
Raj, Ahmed   +2 more
core   +1 more source

Pentaerythritol as an excipient/solid-dispersion carrier for improved solubility and permeability of ursodeoxycholic acid [PDF]

open access: yes, 2018
In this study, the feasibility of using pentaerythritol as a novel excipient/solid-dispersion carrier for enhancing the biopharmaceutical properties of ursodeoxycholic acid (UA) is explored.
Milind Umekar   +5 more
core  

Impact of YAQ001 on the Gut Microbiome, Permeability and Markers of Systemic Inflammation in Patients With Cirrhosis

open access: yesLiver International, Volume 46, Issue 11, November 2026.
ABSTRACT Background & Aims YAQ001 is a novel, non‐absorbable, gut‐restricted, multiporous, carbon bead adsorbent. Pre‐clinical studies and a clinical trial suggested its therapeutic potential and safety in patients with cirrhosis. This substudy aimed to explore the effects of YAQ001 on the gut microbiome and their exploratory association with ...
Jinxia Liu   +54 more
wiley   +1 more source

Effects of Weight Loss Interventions on Gut Microbiota‐Derived Metabolites Linked to Cardiometabolic Health: A Systematic Review and Meta‐Analysis

open access: yesObesity Reviews, Volume 27, Issue 11, November 2026.
ABSTRACT Background Gut microbiota‐derived metabolites are emerging as potential mediators between obesity and cardiometabolic conditions. While weight loss interventions modify microbiota composition, their effects on systemic microbial metabolites remain unclear.
Fernando Q. Iorra   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy